S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE. (23rd June 2022)

• Record Type: Journal Article
• Authors: Rea, D.; Hochhaus, A.; Mauro, M. J.; Minami, Y.; Lomaia, E.; Voloshin, S.; Turkina, A.; Kim, D.-W.; Apperley, J. F.; Cortes, J. E.; Abdo, A.; Fogliatto, L. M.; Kim, D. D. H; le Coutre, P.; Saussele, S.; Annunziata, M.; Hughes, T. P.; Chaudhri, N.; Chee, L.; García-Gutiérrez, V.; Sasaki, K.; Kapoor, S.; Allepuz, A.; Quenet, S.; Bédoucha, V.; Boquimpani, C.
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 56
• Page End: 57
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000843512.62237.dc
• Languages: English
• ISSNs: 2572-9241